Section of Pulmonary Diseases, Tulane University School of Medical, New Orleans, Louisiana 70112, USA.
Respirology. 2010 Jan;15(1):19-31. doi: 10.1111/j.1440-1843.2009.01672.x.
Most pulmonary consultants are called upon to discuss IPF management with their patients. The gravity of IPF treatment discussion is immense in view of the data that 3- and 5-year mortality rates are approximately 50% and 80%, respectively. Although IPF occurs in older patients with comorbid diseases, most patients with IPF die as a direct consequence of their lung fibrosis. Here, the results of recently completed IPF trials and the rationale for ongoing studies are succinctly reviewed. There are a number of novel agents in clinical trials that are in the earlier stages of development, and there is new evidence supporting palliative therapies, which may help in managing symptoms of IPF, such as cough, without necessarily altering the course of the disease. The information provided herein should facilitate informed physician-patient dialogue.
大多数肺科顾问都需要与他们的患者讨论特发性肺纤维化（IPF）的管理。鉴于 3 年和 5 年死亡率分别约为 50%和 80%的数据，IPF 治疗讨论的重要性是巨大的。尽管 IPF 发生在患有合并症的老年患者中，但大多数 IPF 患者的死亡是其肺纤维化的直接后果。在此，简要回顾了最近完成的 IPF 试验的结果和正在进行的研究的基本原理。有许多处于早期开发阶段的新型药物，并且有新的证据支持姑息治疗，这可能有助于控制 IPF 的症状，例如咳嗽，而不一定改变疾病的进程。本文提供的信息应有助于进行知情的医患对话。
